Symptomatic vs AsymptomaticWith Abbott's bombshell announcement yesterday, we are now down to a very simple situation. Can the Sona test really detect the virus pre (or very early) symptoms or not? If the answer is 'yes', then Sona is firmly in the game still. If the answer is 'no', then there is trouble ahead. And here's why:
In the last NR Rowles stated:
"Rapid, point-of-care, antigen tests can make a significant contribution to reducing the spread of COVID-19 by detecting the presence of the virus, potentially before the onset of symptoms"
So, this seems to be a generic statement on Antigen tests rather than on Sona's test. Can Sona actually achieve this? There has been lots of speculation that it can here, on CEO and on twitter but we need to see the proof. Where is the data that suggests this? Someone on Twitter tried to suggest that because there was 60 negatives, then the study was focused on asymptomatic individuals but that is pure speculation which seems to now have been accepted as fact by some investors. This is dangerous.
Abbott's test comes with very clear claims regarding when it is sensitive and when it isn't. Sona needs to do the same, and fast. GLTA